Key result
The 2005 ACC/AHA heart failure guidelines provide updated, stage-specific recommendations for pharmacologic, nonpharmacologic, and cardiac device treatments to optimize clinical care.
Provides a summary of the 2005 ACC/AHA heart failure guidelines to assist clinicians with integrating evidence-based therapies into practice.
Answers are grounded in this paper and cite their sources.
Highlights need for better HF guideline adherence; leaves open strategies to overcome underutilization.
Progress in Cardiovascular Nursing 39H eart failure (HF) is a chronic illness that has grown to near-epidemic proportions.Approximately 5 million Americans have HF, and more than 500,000 cases are newly diagnosed every year. 1 It accounts for approximately 1 million hospitalizations each year, 12-15 million outpatient visits, and more than 300,000 deaths.The 5-year mortality rate is as high as 50%, reaching 70%-80% at 8 years.Total costs of HF will reach an estimated $28 billion per year in the United States alone. 1 These staggering statistics reflect the challenges of providing optimal HF care in the community. 2Despite increasing clinical trial evidence favoring β-blocker, angiotensin-converting enzyme inhibitor (ACEI), cardiac resynchronization, and other therapies, these interventions remain underutilized. 3o assist clinicians with an evidence-based approach to HF care, the American College of Cardiology and the American Heart Association (ACC/ AHA) published original HF clinical practice guidelines in 1995.The 2001 update of the guidelines included a framework of new "stages" of HF that emphasized the development and progression of the condition.In September 2005, the guidelines were once again revised to reflect the most recent progress in treating chronic HF, encompassing pharmacologic, nonpharmacologic, and cardiac device treatment options.A summary of the stage-specific treatments for HF is shown in Figure 1.Clinical practice guidelines are intended to guide, standardize, and simplify care, ultimately assisting with integrating therapies into practice for optimal care.The purpose of this column is to summarize new and important recommendations from the latest HF guidelines.
No takes yet. Share an insight, caveat, or question.
Macabasco‐O’Connell et al. (2006) conducted a review in Heart failure. 2005 ACC/AHA Heart Failure guidelines was evaluated. The 2005 ACC/AHA heart failure guidelines provide updated, stage-specific recommendations for pharmacologic, nonpharmacologic, and cardiac device treatments to optimize clinical care.
Synapse has enriched 10 related papers. Consider them for comparative context: